AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01592318
Drug: danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablet, single oral dose
Trial: NCT01592318
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination tablet with danoprevir, single oral dose
Trial: NCT01592318
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reference tablet, single oral dose
Trial: NCT03292250
Drug: Poziotinib
RxNorm normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Trial: NCT03292250
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dose 200 mg twice per day orally according to study protocol.
Trial: NCT03292250
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
Trial: NCT02045901
Drug: Diclegis
RxNorm normalized name: Diclegis
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
Trial: NCT00108004
Drug: pramlintide acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
Trial: NCT00128401
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001725
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01848925
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for Sickle Cell treatment, 15 mg/kg.
Trial: NCT00015886
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 milligrams per meter squared intraveneously
Trial: NCT01525914
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dutasteride 0.5mg daily
Trial: NCT01023035
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg given three times a day (TID), orally (PO)
Trial: NCT01023035
Drug: Peginterferon alfa-2b (PEG2b)
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 µg/kg/week given subcutaneously (SC)
Trial: NCT01023035
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
Trial: NCT03292250
Drug: Durvalumab,Tremelimumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Trial: NCT00512395
Drug: epidural analgesia (Duracain/Fentanyl/Naropin)
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
Trial: NCT02389972
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02077166
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02077166
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02077166
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003334
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03682718
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprstol inserted vaginally for induction of labor
Trial: NCT01764737
Drug: VX15/2503
RxNorm normalized name: VX15/2503
DrugBank: Pepinemab (DB15155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intravenous administration
Trial: NCT01023035
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
Trial: NCT02370238
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
Trial: NCT02370238
Drug: Reparixin
RxNorm normalized name: Reparixin
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
Trial: NCT02134990
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotheraphy
Trial: NCT06762509
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Local injection of botulinum toxin type A was given at the time of enrollment
Trial: NCT03630991
Drug: Edetate Calcium Disodium
RxNorm normalized name: Edetate Calcium Disodium
DrugBank: Edetate calcium disodium anhydrous (DB14598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03630991
Drug: Succimer
RxNorm normalized name: Succimer
DrugBank: Succimer (DB00566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00001230
Drug: Diethylcarbamazine
RxNorm normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
Trial: NCT03934372
Drug: Ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
Trial: NCT02030964
Drug: DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02030964
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03732703
Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Trial: NCT00943748
Drug: deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
Trial: NCT00956072
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive imatinib mesylate
Trial: NCT00198055
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
Trial: NCT01377220
Drug: 11C-Choline
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-Choline : 6MBq/kg on direct intravenous on one minute.
Trial: NCT00003126
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
Trial: NCT01935830
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
Trial: NCT01935830
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
Trial: NCT02291991
Drug: GX-E2
RxNorm normalized name: GX-G8
DrugBank: GX-G8 (DB18196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
Trial: NCT00274339
Drug: Prevacid 30mg BID
RxNorm normalized name: lansoprazole 30 MG [Prevacid]
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01288716
Drug: Arbaclofen
RxNorm normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03590210
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
Trial: NCT03590210
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 2 to 16 240 mg IV over 30 minutes, q3w
Trial: NCT01656057
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin + acetaminophen dissolved in 50 ml of water
Trial: NCT01656057
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam + acetaminophen dissolved in 50 ml of water
Trial: NCT03362814
Drug: Ravidasvir
RxNorm normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravidasvir 200mg tablet administered orally once daily
Trial: NCT03362814
Drug: Danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir 100mg tablet administered orally twice daily
Trial: NCT03362814
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 100mg tablet administered orally twice daily
Trial: NCT03362814
Drug: Ribavirin 100 MG
RxNorm normalized name: ribavirin 100 MG
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
Trial: NCT03362814
Drug: Ribavirin Placebo
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
Trial: NCT00799058
Drug: dapivirine 4789
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dapivirine gel 4789, 0.05%, 2.5g applied once daily
Trial: NCT03732703
Drug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Trial: NCT03732703
Drug: Selinexor, dexamethasone, ixazomib, pomalidomide
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
Trial: NCT03064490
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
Trial: NCT03309592
Drug: Ambrisentan Pill
RxNorm normalized name: ambrisentan Pill
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as stated in Arm/Group Descriptions
Trial: NCT00799058
Drug: dapivirine gel 4759
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dapivirine gel 4759, 0.05%, 2.5g applied once daily
Trial: NCT00462904
Drug: BPI
RxNorm normalized name: BPI-2009
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
Trial: NCT03213444
Drug: adjuvant chemotherapy with 5-FU isolated
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients submitted to adjuvant chemotherapy with 5-FU isolated
Trial: NCT03936933
Drug: Goserelin acetate 3.6 mg Injection
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.6 mg, Subcutaneously at every 28 days
Trial: NCT03309592
Drug: Tadalafil Pill
RxNorm normalized name: tadalafil Pill
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered as stated in Arm/Group Descriptions
Trial: NCT04603040
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
Trial: NCT03213444
Drug: adjuvant chemotherapy with 5-FU associated with oxaliplatin
RxNorm normalized name: 5-FU
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
Trial: NCT02355639
Drug: Clobetasol propionate 0.05 % ointment
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02355639
Drug: Betamethasone dipropionate 0.064 % ointment
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02355639
Drug: Petrolatum ointment
RxNorm normalized name: GERI PROTECT Petrolatum Ointment
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04575610
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
Trial: NCT00165555
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as a heated one-hour lavage to the hemithorax after surgery.
Trial: NCT00165555
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously over 6 hours after the cisplatin lavage.
Trial: NCT02158507
Drug: Combination of Veliparib + Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
Trial: NCT00671216
Drug: GSK233705 and GW642444
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
Trial: NCT03757858
Drug: Anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
Trial: NCT03409588
Drug: Adempas
RxNorm normalized name: Adempas
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
Trial: NCT00126438
Drug: 123I-mIBG (meta-iodobenzylguanidine)
RxNorm normalized name: mIBG
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose
Trial: NCT04786158
Drug: Apomorphine
RxNorm normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reporting the effects of subcutaneous apomorphine on pain and on quality of life
Trial: NCT00941330
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg daily by mouth for 6 to 12 months.
Trial: NCT00941330
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Trial: NCT00941330
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Trial: NCT00818753
Drug: dabigatran 110 mg
RxNorm normalized name: dabigatran 110 mg oral capsule
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dabigatran dosages with unfractionated heparin
Trial: NCT00818753
Drug: dabigatran 150 mg
RxNorm normalized name: dabigatran 150 mg oral capsule
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dabigatran dosages with unfractionated heparin